Cipla's animal health division operates mainly in the farm animal segment and its main products include antimicrobials, endectocides, proton pump inhibitors, non-steroidal anti-inflammatory drugs, and supplements.
In a statement, Cipla South Africa CEO Paul Miller said that the company will increase its focus and efforts in advancing healthcare for all South Africans and will grow its portfolio of quality and affordable products and therapies.
The sale of the animal health business is in line with the company's strategy to cut down on non-core businesses and focus on key areas, including the respiratory segment. Its key markets include India, South Africa and the US.
Last year, it exited from several markets to reduce costs and complexities and also sold its stake in clinical stage biopharmaceutical company Chase Pharmaceuticals to Allergan.
From Cipla’s folio